Department of Medical Parasitology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Braz J Infect Dis. 2011 Sep-Oct;15(5):442-8. doi: 10.1016/s1413-8670(11)70225-2.
OBJECTIVES: Apoptosis is the process of programmed cell death (PCD) that occurs in both animal and plant cells. Protozoan parasites possess metacaspase and these caspase-related proteases could be involved in the PCD pathways in these organisms. Therefore we analyzed the activities of metacaspase and PARP genes in Leishmania infantum (MCAN/IR/96/LON49) treated with miltefosine. MATERIALS AND METHODS: Anti-leishmania activity of miltefosine was studied by treatment of cultured promastigotes with various concentration of miltefosine. MTT assay and Annexin-V FLUOS staining by using FACS flow cytometry methods were used. Cytotoxic potential of HePC on the amastigots of L.infantum was evaluated in J774 cell line. In addition, metacaspase and PARP genes expression of treated L. infantum were studied. RESULTS: Miltefosine led to dose-dependent death of L. infantum with features compatible with apoptosis. Over expression of metacaspase and PARP was seen 6 hr after treatment. CONCLUSIONS: Our study showed that miltefosine exerts cytotoxic effect on L. infantum via an apoptotic-related mechanism.
目的:细胞凋亡是动物和植物细胞中发生的程序性细胞死亡(PCD)过程。原生动物寄生虫具有原半胱氨酸蛋白酶,这些半胱氨酸蛋白酶相关蛋白酶可能参与这些生物的 PCD 途径。因此,我们分析了米替福新处理的婴儿利什曼原虫(MCAN/IR/96/LON49)中半胱天冬酶和 PARP 基因的活性。
材料和方法:通过用不同浓度的米替福新处理培养的前鞭毛体来研究米替福新的抗利什曼原虫活性。使用 MTT 测定法和流式细胞术方法的 Annexin-V FLUOS 染色法。在 J774 细胞系中评估 HePC 对婴儿利什曼原虫的无鞭毛体的细胞毒性潜力。此外,研究了经处理的婴儿利什曼原虫中半胱天冬酶和 PARP 基因的表达。
结果:米替福新导致婴儿利什曼原虫呈剂量依赖性死亡,其特征与凋亡一致。治疗后 6 小时即可观察到半胱天冬酶和 PARP 的过度表达。
结论:我们的研究表明,米替福新通过与凋亡相关的机制对婴儿利什曼原虫发挥细胞毒性作用。
Braz J Infect Dis. 2011
Antimicrob Agents Chemother. 2008-10
Antimicrob Agents Chemother. 2004-3
Antimicrob Agents Chemother. 2004-8
Mem Inst Oswaldo Cruz. 2011-6
Iran J Parasitol. 2025
Iran J Parasitol. 2024
Front Pharmacol. 2019-7-18
Microb Cell. 2018-8-1
J Evid Based Complementary Altern Med. 2017-1
Antimicrob Agents Chemother. 2014-10
Evid Based Complement Alternat Med. 2013-3-21